FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ATP2A2-ATP2A3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ATP2A2-ATP2A3
FusionPDB ID: 7827
FusionGDB2.0 ID: 7827
HgeneTgene
Gene symbol

ATP2A2

ATP2A3

Gene ID

488

489

Gene nameATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3
SynonymsATP2B|DAR|DD|SERCA2SERCA3
Cytomap

12q24.11

17p13.2

Type of geneprotein-codingprotein-coding
Descriptionsarcoplasmic/endoplasmic reticulum calcium ATPase 2ATPase Ca++ transporting cardiac muscle slow twitch 2ATPase, Ca++ dependent, slow-twitch, cardiac muscle-2SR Ca(2+)-ATPase 2calcium pump 2calcium-transporting ATPase sarcoplasmic reticulum type, slowsarcoplasmic/endoplasmic reticulum calcium ATPase 3ATPase, Ca(2+)-transporting, ubiquitousATPase, Ca++ transporting, ubiquitousSR Ca(2+)-ATPase 3adenosine triphosphatase, calciumcalcium pump 3calcium-translocating P-type ATPasesarco/endoplasmic ret
Modification date2020031320200313
UniProtAcc

P16615

Main function of 5'-partner protein: FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen (PubMed:16402920). Involved in autophagy in response to starvation. Upon interaction with VMP1 and activation, controls ER-isolation membrane contacts for autophagosome formation (PubMed:28890335). Also modulates ER contacts with lipid droplets, mitochondria and endosomes (PubMed:28890335). {ECO:0000269|PubMed:16402920, ECO:0000269|PubMed:28890335}.; FUNCTION: [Isoform 2]: Involved in the regulation of the contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated Ca(2+) signaling pathways via its interaction with TMEM64 which is critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS generation necessary for proper osteoclast generation. Association between TMEM64 and SERCA2 in the ER leads to cytosolic Ca(2+) spiking for activation of NFATC1 and production of mitochondrial ROS, thereby triggering Ca(2+) signaling cascades that promote osteoclast differentiation and activation. {ECO:0000250|UniProtKB:O55143}.

Q93084

Main function of 5'-partner protein: FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of calcium. Transports calcium ions from the cytosol into the sarcoplasmic/endoplasmic reticulum lumen. Contributes to calcium sequestration involved in muscular excitation/contraction. {ECO:0000269|PubMed:11956212, ECO:0000269|PubMed:15028735}.
Ensembl transtripts involved in fusion geneENST idsENST00000308664, ENST00000395494, 
ENST00000539276, ENST00000550248, 
ENST00000552636, 
ENST00000352011, 
ENST00000359983, ENST00000397039, 
ENST00000397043, ENST00000309890, 
ENST00000397035, ENST00000397041, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score17 X 22 X 11=41145 X 3 X 5=75
# samples 275
** MAII scorelog2(27/4114*10)=-3.9295104814741
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/75*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ATP2A2 [Title/Abstract] AND ATP2A3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ATP2A2 [Title/Abstract] AND ATP2A3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ATP2A2(110777208)-ATP2A3(3844948), # samples:1
Anticipated loss of major functional domain due to fusion event.ATP2A2-ATP2A3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-ATP2A3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-ATP2A3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-ATP2A3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneATP2A2

GO:0032469

endoplasmic reticulum calcium ion homeostasis

16402920

HgeneATP2A2

GO:0032470

positive regulation of endoplasmic reticulum calcium ion concentration

16402920

HgeneATP2A2

GO:0070588

calcium ion transmembrane transport

16402920

HgeneATP2A2

GO:1903515

calcium ion transport from cytosol to endoplasmic reticulum

16402920

TgeneATP2A3

GO:0006919

activation of cysteine-type endopeptidase activity involved in apoptotic process

16725111

TgeneATP2A3

GO:0070059

intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress

16725111

TgeneATP2A3

GO:0070588

calcium ion transmembrane transport

9843705|11956212

TgeneATP2A3

GO:1903515

calcium ion transport from cytosol to endoplasmic reticulum

15028735



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:110777208/chr17:3844948)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ATP2A2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ATP2A3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000308664ATP2A2chr12110777208+ENST00000397035ATP2A3chr173844948-4725221632937601143
ENST00000308664ATP2A2chr12110777208+ENST00000397041ATP2A3chr173844948-5218221632936701113
ENST00000308664ATP2A2chr12110777208+ENST00000309890ATP2A3chr173844948-5319221632937601143
ENST00000395494ATP2A2chr12110777208+ENST00000397035ATP2A3chr173844948-4533202421835681116
ENST00000395494ATP2A2chr12110777208+ENST00000397041ATP2A3chr173844948-5026202421834781086
ENST00000395494ATP2A2chr12110777208+ENST00000309890ATP2A3chr173844948-5127202421835681116
ENST00000539276ATP2A2chr12110777208+ENST00000397035ATP2A3chr173844948-4160165110931951028
ENST00000539276ATP2A2chr12110777208+ENST00000397041ATP2A3chr173844948-465316511093105998
ENST00000539276ATP2A2chr12110777208+ENST00000309890ATP2A3chr173844948-4754165110931951028

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000308664ENST00000397035ATP2A2chr12110777208+ATP2A3chr173844948-0.0022857570.9977143
ENST00000308664ENST00000397041ATP2A2chr12110777208+ATP2A3chr173844948-0.0030595590.9969405
ENST00000308664ENST00000309890ATP2A2chr12110777208+ATP2A3chr173844948-0.0019566040.9980434
ENST00000395494ENST00000397035ATP2A2chr12110777208+ATP2A3chr173844948-0.0023894020.99761057
ENST00000395494ENST00000397041ATP2A2chr12110777208+ATP2A3chr173844948-0.0021352530.9978648
ENST00000395494ENST00000309890ATP2A2chr12110777208+ATP2A3chr173844948-0.0019752330.9980248
ENST00000539276ENST00000397035ATP2A2chr12110777208+ATP2A3chr173844948-0.0014262690.9985738
ENST00000539276ENST00000397041ATP2A2chr12110777208+ATP2A3chr173844948-0.0018454920.99815446
ENST00000539276ENST00000309890ATP2A2chr12110777208+ATP2A3chr173844948-0.0011711950.9988288

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP2A2-ATP2A3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ATP2A2chr12110777208ATP2A3chr173844948165145KERWGSNELPAEEGKTLLELVIEQFE
ATP2A2chr12110777208ATP2A3chr1738449482024160KERWGSNELPAEEGKTLLELVIEQFE
ATP2A2chr12110777208ATP2A3chr1738449482216160KERWGSNELPAEEGKTLLELVIEQFE

Top

Potential FusionNeoAntigen Information of ATP2A2-ATP2A3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP2A2-ATP2A3_110777208_3844948.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:13AEEGKTLL0.94340.98771018
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B07:10LPAEEGKTL0.9950.5128817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:01LPAEEGKTL0.98760.9676817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:03LPAEEGKTL0.98130.9586817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:08LPAEEGKTL0.97970.9292817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:03EEGKTLLEL0.97450.98421120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B45:01EEGKTLLEL0.9560.8561120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:05LPAEEGKTL0.93990.8545817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B53:01LPAEEGKTL0.93840.6875817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:01EEGKTLLEL0.90170.95981120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B15:10LPAEEGKTL0.85280.8238817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B15:37LPAEEGKTL0.84450.8137817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:04LPAEEGKTL0.83170.9876817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:02LPAEEGKTL0.83170.9876817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:02LPAEEGKTL0.79230.6023817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:01LPAEEGKTL0.6850.9913817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:01LPAEEGKTL0.6180.5712817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:13EEGKTLLEL0.47620.97661120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B81:01LPAEEGKTL0.21780.5122817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B82:01LPAEEGKTL0.07660.6282817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:08LPAEEGKTLL0.96590.8662818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:03LPAEEGKTLL0.95940.9241818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B53:01LPAEEGKTLL0.9150.5229818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:13AEEGKTLLEL0.85080.9681020
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:04LPAEEGKTLL0.82230.9788818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:02LPAEEGKTLL0.82230.9788818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B82:01LPAEEGKTLL0.55830.542818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:03ELPAEEGKTL0.53390.9179717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B82:01ELPAEEGKTL0.5080.5282717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:02ELPAEEGKTL0.40910.9305717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:04ELPAEEGKTL0.40910.9305717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:03NELPAEEGKTL0.99840.9661617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:03NELPAEEGKTL0.99840.9582617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:02NELPAEEGKTL0.99710.9764617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:04NELPAEEGKTL0.99710.9764617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:08AEEGKTLL0.980.88491018
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B07:12LPAEEGKTL0.97270.6686817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B14:03LPAEEGKTL0.93560.8943817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B56:04LPAEEGKTL0.87880.5296817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:12LPAEEGKTL0.83170.9876817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:09LPAEEGKTL0.74020.852817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:10LPAEEGKTL0.73830.9922817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:07LPAEEGKTL0.64680.8498817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:08EEGKTLLEL0.63770.90241120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B78:01LPAEEGKTL0.5910.7164817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B42:02LPAEEGKTL0.43930.9449817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B42:01LPAEEGKTL0.39410.9397817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:08LPAEEGKTL0.37750.5707817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:10AEEGKTLLEL0.98580.5511020
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B07:12LPAEEGKTLL0.98390.5882818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:08AEEGKTLLEL0.9550.82491020
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B42:02LPAEEGKTLL0.83170.8938818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:12LPAEEGKTLL0.82230.9788818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B42:01LPAEEGKTLL0.8010.8859818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:10LPAEEGKTLL0.69240.9883818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:10ELPAEEGKTL0.42490.9571717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:12ELPAEEGKTL0.40910.9305717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:12NELPAEEGKTL0.99710.9764617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:10NELPAEEGKTL0.99420.9806617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B40:04AEEGKTLL0.99980.77991018
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B41:03AEEGKTLL0.95080.58511018
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B40:04EEGKTLLEL0.99590.7511120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:23LPAEEGKTL0.98920.97817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:77LPAEEGKTL0.98760.9676817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:13LPAEEGKTL0.97770.9597817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:07EEGKTLLEL0.97450.98421120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:13EEGKTLLEL0.97450.98421120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:26EEGKTLLEL0.97450.98421120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:30LPAEEGKTL0.9460.9338817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:17LPAEEGKTL0.9460.9338817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:24LPAEEGKTL0.94480.9629817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:11LPAEEGKTL0.92370.9653817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:08EEGKTLLEL0.91410.96711120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:04EEGKTLLEL0.91040.96251120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:05EEGKTLLEL0.90170.95981120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:22LPAEEGKTL0.89090.519817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B56:02LPAEEGKTL0.87880.5296817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:06EEGKTLLEL0.8710.96791120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B55:04LPAEEGKTL0.86910.5481817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:03EEGKTLLEL0.83770.95671120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:09LPAEEGKTL0.83170.9876817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B53:02LPAEEGKTL0.79890.6884817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B67:01LPAEEGKTL0.74430.9614817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:11EEGKTLLEL0.73770.93421120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:06LPAEEGKTL0.70530.5616817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:09LPAEEGKTL0.68040.6021817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:11LPAEEGKTL0.67730.9449817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B78:02LPAEEGKTL0.65110.771817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B41:03EEGKTLLEL0.620.61871120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:14LPAEEGKTL0.60980.5514817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B07:26LPAEEGKTL0.56720.6603817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B15:09LPAEEGKTL0.49220.9111817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B08:12LPAEEGKTL0.47860.9656817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:21LPAEEGKTL0.45610.6976817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B39:02EEGKTLLEL0.44030.97651120
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B18:07LPAEEGKTL0.15010.9403817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B82:02LPAEEGKTL0.07660.6282817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:43LPAEEGKTL0.01010.9377817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B15:08LPAEEGKTL0.00960.935817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B15:11LPAEEGKTL0.00850.9227817
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B40:04AEEGKTLLEL0.9950.77081020
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:13LPAEEGKTLL0.94970.926818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B07:26LPAEEGKTLL0.8430.5616818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B41:03AEEGKTLLEL0.82240.51421020
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:09LPAEEGKTLL0.82230.9788818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B67:01LPAEEGKTLL0.70830.8999818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B51:06LPAEEGKTLL0.62180.5024818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B82:02LPAEEGKTLL0.55830.542818
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B82:02ELPAEEGKTL0.5080.5282717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:09ELPAEEGKTL0.40910.9305717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B67:01ELPAEEGKTL0.3440.833717
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B40:04NELPAEEGKTL0.99890.7192617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:26NELPAEEGKTL0.99840.9661617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:13NELPAEEGKTL0.99840.9661617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B44:07NELPAEEGKTL0.99840.9661617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B35:09NELPAEEGKTL0.99710.9764617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B67:01NELPAEEGKTL0.99630.781617
ATP2A2-ATP2A3chr12110777208chr1738449482216HLA-B41:03NELPAEEGKTL0.98110.7456617

Top

Potential FusionNeoAntigen Information of ATP2A2-ATP2A3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of ATP2A2-ATP2A3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6139NELPAEEGKTLLELATP2A2ATP2A3chr12110777208chr1738449482216

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP2A2-ATP2A3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6139NELPAEEGKTLLEL-7.9962-8.1096
HLA-B14:023BVN6139NELPAEEGKTLLEL-5.70842-6.74372
HLA-B52:013W396139NELPAEEGKTLLEL-6.83737-6.95077
HLA-B52:013W396139NELPAEEGKTLLEL-4.4836-5.5189
HLA-A11:014UQ26139NELPAEEGKTLLEL-10.0067-10.1201
HLA-A11:014UQ26139NELPAEEGKTLLEL-9.03915-10.0745
HLA-A24:025HGA6139NELPAEEGKTLLEL-6.56204-6.67544
HLA-A24:025HGA6139NELPAEEGKTLLEL-5.42271-6.45801
HLA-B44:053DX86139NELPAEEGKTLLEL-7.85648-8.89178
HLA-B44:053DX86139NELPAEEGKTLLEL-5.3978-5.5112
HLA-A02:016TDR6139NELPAEEGKTLLEL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ATP2A2-ATP2A3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ATP2A2-ATP2A3chr12110777208chr1738449481018AEEGKTLLTTTGTGAAGGGGGCTCCTGAGAGT
ATP2A2-ATP2A3chr12110777208chr1738449481020AEEGKTLLELTTTGTGAAGGGGGCTCCTGAGAGTGTGATC
ATP2A2-ATP2A3chr12110777208chr1738449481120EEGKTLLELGTGAAGGGGGCTCCTGAGAGTGTGATC
ATP2A2-ATP2A3chr12110777208chr173844948617NELPAEEGKTLATGAGCAAGATGTTTGTGAAGGGGGCTCCTGAG
ATP2A2-ATP2A3chr12110777208chr173844948717ELPAEEGKTLAGCAAGATGTTTGTGAAGGGGGCTCCTGAG
ATP2A2-ATP2A3chr12110777208chr173844948817LPAEEGKTLAAGATGTTTGTGAAGGGGGCTCCTGAG
ATP2A2-ATP2A3chr12110777208chr173844948818LPAEEGKTLLAAGATGTTTGTGAAGGGGGCTCCTGAGAGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of ATP2A2-ATP2A3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerATP2A2-ATP2A3chr12110777208ENST00000308664chr173844948ENST000003098902397N

Top

Potential target of CAR-T therapy development for ATP2A2-ATP2A3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneATP2A2chr12:110777208chr17:3844948ENST00000308664+1221254_273514998.0TransmembraneHelical%3B Name%3D3
HgeneATP2A2chr12:110777208chr17:3844948ENST00000308664+1221296_313514998.0TransmembraneHelical%3B Name%3D4
HgeneATP2A2chr12:110777208chr17:3844948ENST00000308664+122149_69514998.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110777208chr17:3844948ENST00000308664+122190_110514998.0TransmembraneHelical%3B Name%3D2
HgeneATP2A2chr12:110777208chr17:3844948ENST00000395494+1119254_2734871016.0TransmembraneHelical%3B Name%3D3
HgeneATP2A2chr12:110777208chr17:3844948ENST00000395494+1119296_3134871016.0TransmembraneHelical%3B Name%3D4
HgeneATP2A2chr12:110777208chr17:3844948ENST00000395494+111949_694871016.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110777208chr17:3844948ENST00000395494+111990_1104871016.0TransmembraneHelical%3B Name%3D2
HgeneATP2A2chr12:110777208chr17:3844948ENST00000539276+1220254_2735141043.0TransmembraneHelical%3B Name%3D3
HgeneATP2A2chr12:110777208chr17:3844948ENST00000539276+1220296_3135141043.0TransmembraneHelical%3B Name%3D4
HgeneATP2A2chr12:110777208chr17:3844948ENST00000539276+122049_695141043.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110777208chr17:3844948ENST00000539276+122090_1105141043.0TransmembraneHelical%3B Name%3D2
TgeneATP2A3chr12:110777208chr17:3844948ENST000003098901122758_77701030.0TransmembraneHelical%3B Name%3D5
TgeneATP2A3chr12:110777208chr17:3844948ENST000003098901122829_85101030.0TransmembraneHelical%3B Name%3D7
TgeneATP2A3chr12:110777208chr17:3844948ENST000003098901122898_91701030.0TransmembraneHelical%3B Name%3D8
TgeneATP2A3chr12:110777208chr17:3844948ENST000003098901122931_94901030.0TransmembraneHelical%3B Name%3D9
TgeneATP2A3chr12:110777208chr17:3844948ENST000003098901122965_98501030.0TransmembraneHelical%3B Name%3D10
TgeneATP2A3chr12:110777208chr17:3844948ENST000003520111122758_77701044.0TransmembraneHelical%3B Name%3D5
TgeneATP2A3chr12:110777208chr17:3844948ENST000003520111122829_85101044.0TransmembraneHelical%3B Name%3D7
TgeneATP2A3chr12:110777208chr17:3844948ENST000003520111122898_91701044.0TransmembraneHelical%3B Name%3D8
TgeneATP2A3chr12:110777208chr17:3844948ENST000003520111122931_94901044.0TransmembraneHelical%3B Name%3D9
TgeneATP2A3chr12:110777208chr17:3844948ENST000003520111122965_98501044.0TransmembraneHelical%3B Name%3D10
TgeneATP2A3chr12:110777208chr17:3844948ENST000003599831123758_77701053.0TransmembraneHelical%3B Name%3D5
TgeneATP2A3chr12:110777208chr17:3844948ENST000003599831123829_85101053.0TransmembraneHelical%3B Name%3D7
TgeneATP2A3chr12:110777208chr17:3844948ENST000003599831123898_91701053.0TransmembraneHelical%3B Name%3D8
TgeneATP2A3chr12:110777208chr17:3844948ENST000003599831123931_94901053.0TransmembraneHelical%3B Name%3D9
TgeneATP2A3chr12:110777208chr17:3844948ENST000003599831123965_98501053.0TransmembraneHelical%3B Name%3D10
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970351123758_77701266.3333333333333TransmembraneHelical%3B Name%3D5
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970351123829_85101266.3333333333333TransmembraneHelical%3B Name%3D7
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970351123898_91701266.3333333333333TransmembraneHelical%3B Name%3D8
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970351123931_94901266.3333333333333TransmembraneHelical%3B Name%3D9
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970351123965_98501266.3333333333333TransmembraneHelical%3B Name%3D10
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970411121758_77701000.0TransmembraneHelical%3B Name%3D5
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970411121829_85101000.0TransmembraneHelical%3B Name%3D7
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970411121898_91701000.0TransmembraneHelical%3B Name%3D8
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970411121931_94901000.0TransmembraneHelical%3B Name%3D9
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970411121965_98501000.0TransmembraneHelical%3B Name%3D10
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970431121758_7770999.0TransmembraneHelical%3B Name%3D5
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970431121829_8510999.0TransmembraneHelical%3B Name%3D7
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970431121898_9170999.0TransmembraneHelical%3B Name%3D8
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970431121931_9490999.0TransmembraneHelical%3B Name%3D9
TgeneATP2A3chr12:110777208chr17:3844948ENST000003970431121965_9850999.0TransmembraneHelical%3B Name%3D10

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ATP2A2-ATP2A3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ATP2A2-ATP2A3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource